文献速递甲状腺疾病

超声引导激光消融治疗甲状腺微小乳头状癌:10年回顾性研究

Long-Term Efficacy of Ultrasound-Guided Laser Ablation for Papillary Thyroid Microcarcinoma: Results of a 10-Year Retrospective Study.
PubMed 文献 · Thyroid · 2021-10-05

该10年回顾性研究评估了激光消融(LA)治疗单发低危甲状腺微小乳头状癌(PTMC)的远期疗效与安全性。90例患者接受单次LA,平均随访112个月,消融区12个月消失率达100%,5例(5.5%)在未治疗区出现新病灶,1例(1.1%)检出转移淋巴结但判为术前未发现的转移而非复发。结论认为LA对低危PTMC有效且安全,治疗前需全面评估多灶性和淋巴结转移状态。

要点

  • LA治疗低危PTMC后12个月消融区消失率达100%,10年随访疗效稳定。
  • 5.5%患者在未治疗区出现新PTMC病灶,1.1%检出转移淋巴结但非复发。
  • 治疗前需全面评估多灶性和淋巴结转移状态,以筛选适合LA的患者。

核心结论

  • 激光消融对低危甲状腺微小乳头状癌有效且安全,但治疗前需全面评估多灶性和淋巴结转移状态。

研究设计与样本

  • 10年回顾性研究,纳入2008至2011年间拒绝或不适合手术、经细针穿刺细胞学诊断的低危单发PTMC患者,共90例90个病灶接受单次激光消融。

主要发现

  • 平均随访112个月,消融后3-10个月所有消融区消失或呈瘢痕,12个月后消失率达100%。
  • 治疗后甲状腺激素和自身抗体水平无显著变化。
  • 3例出现暂时性声音改变,均在1个月内恢复。
  • 5例(5.5%)在治疗后17-56个月于既往未治疗区域检出新的PTMC病灶。
  • 1例(1.1%)在治疗后2个月内检出转移淋巴结,判定为术前未发现的转移而非复发;所有复发患者均接受手术,5年以上无复发病例。

临床怎么用

  • 激光消融可作为拒绝或不适合手术的低危单发PTMC患者的治疗选择。
  • 治疗前需通过超声等检查全面评估多灶性和淋巴结转移状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The aim of this study was to evaluate the 10-year efficacy and safety of laser ablation (LA) for the treatment of solitary papillary thyroid microcarcinoma (PTMC). Methods: LA was performed on patients with low-risk PTMC (diagnosed using fine-needle aspiration cytology) who refused or were ineligible for surgery between 2008 and 2011. Ultrasonography was performed to evaluate the ablated volumes and potential recurrences on the day after the procedure, as well as at 1 week, 1, 3, and 6 months, and every 6 months thereafter for 10 years. Computed tomography (CT) with contrast enhancement and positron emission tomography/CT was performed to evaluate local recurrences and distant metastases. Results: A total of 90 PTMCs in 90 patients were treated in a single session of LA, and the procedure was well tolerated by the patients. The mean follow-up duration was 112 months. By 3-10 months after the LA, all the ablation areas had disappeared or presented as scars. The disappearance rate was 100% after 12 months. Thyroid hormone and autoantibody levels did not change significantly after the treatment. Three patients experienced transient voice changes, but each recovered within 1 month. Additional PTMC foci were subsequently detected in previously untreated areas in five patients (5.5%) 17-56 months after the treatment. A metastatic lymph node was detected in one patient (1.1%) within two months of the treatment; however, it was determined to be an undetected cancer metastasis, rather than a recurrence. All the patients with recurrence underwent surgery, and there were no instances of recurrence after >5 years. Conclusions: LA is effective and safe for the treatment of low-risk PTMCs. A thorough examination of multifocality and lymph node metastasis status is required before considering LA treatment.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Kim HJ, Chung SM, Kim H, et al. Long-Term Efficacy of Ultrasound-Guided Laser Ablation for Papillary Thyroid Microcarcinoma: Results of a 10-Year Retrospective Study. Thyroid. 2021. PMID: 34445885. doi:10.1089/thy.2021.0151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。